Recognizing the First Symptoms of Tysabri-Associated PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or someone you know is taking Tysabri, understanding the earliest symptoms of progressive multifocal leukoencephalopathy (PML) can be critical for timely intervention. The medical community has long recognized that early detection of PML significantly improves prognosis, and this page provides a clear timeline of symptom onset and diagnostic steps to help you stay informed.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal considerations regarding the statute of limitations for filing a claim, is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. PML is caused by the JC virus, which typically remains dormant in immunocompetent individuals but can reactivate in patients receiving immunosuppressive therapies. Tysabri works by binding to alpha-4 integrins on immune cells, preventing their migration into the central nervous system. While this mechanism reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance in the brain, allowing JC virus to replicate unchecked and cause PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The label advises that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication of the condition. The clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and sometimes seizures. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Because PML often leads to severe disability or death, early recognition and discontinuation of Tysabri are essential, though outcomes remain poor even with intervention.

Legal Considerations and Statute of Limitations in Illinois

From a risk perspective, the adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The boxed warning and the TOUCH Prescribing Program, which requires patients to read a Medication Guide and understand the risks, were implemented to mitigate harm (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some affected patients have argued that these warnings were insufficient or that the risks were not adequately communicated before treatment began. For Illinois residents, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri-induced PML is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because PML can develop months to years after starting Tysabri, and symptoms may be initially misattributed to multiple sclerosis itself. The "discovery rule" in Illinois may extend the filing deadline if the patient could not reasonably have known the cause of their injury earlier. Settlement considerations for affected patients often involve evaluating the severity of the PML, the degree of disability, medical expenses, lost income, and pain and suffering. Because PML is frequently devastating, settlements or verdicts can be substantial. However, the statute of limitations imposes a strict deadline, and failure to file within the prescribed period can bar recovery entirely. Patients or their families should consult with legal counsel experienced in pharmaceutical litigation to assess their specific circumstances and ensure timely action. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML through a well-understood mechanistic pathway involving impaired immune surveillance in the brain. The drug's labeling identifies key risk factors and mandates monitoring, but despite these measures, PML continues to occur. For Illinois patients harmed by Tysabri-associated PML, the statute of limitations is a critical factor that requires prompt legal evaluation to preserve any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Illinois?

In Illinois, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri-induced PML is generally two years from the date the injury was discovered or should have been discovered. The discovery rule may extend this deadline if the patient could not reasonably have known the cause earlier.

What are the risk factors for PML in Tysabri patients?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.